about
Non-coronary atherosclerosisSubclavian stenosis/occlusion in patients with subclavian steal and previous bypass of internal mammary interventricular anterior artery: medical or surgical treatment?Classification, epidemiology, risk factors, and natural history of peripheral arterial diseaseA rare case of a coronary artery anomaly detected on multidetector computed tomography.Influence of climatic variables on acute myocardial infarction hospital admissions.Effects of ambient temperature, humidity, and other meteorological variables on hospital admissions for angina pectoris.Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow upModerate alcohol use and health: a consensus document.Critical limb ischemia: definition and natural history.The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBSCost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4.Evaluation of C-reactive protein in primary and secondary prevention.Pharmacological therapy in children with atrial fibrillation and atrial flutter.The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome.ST segment elevations: always a marker of acute myocardial infarction?Risk factors for contrast induced nephropathy: a study among Italian patients.Biomarkers in heart failure.ICD implantation in noncompaction of the left ventricular myocardium: a case report.Protrhombotic effects of contraceptives.Patent foramen ovale and thromboembolic complications.Atherosclerosis, degenerative aortic stenosis and statins.Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study.Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers.Methods to investigate coronary microvascular function in clinical practice.Task force on: 'Early markers of atherosclerosis: influence of age and sex'.Speckle tracking analysis: a new tool for left atrial function analysis in systemic hypertension: an overview.Ventricular-vascular coupling in hypertension: methodological considerations and clinical implications.Cardiovascular health in migrants: current status and issues for prevention. A collaborative multidisciplinary task force report.The controversial relationship between exercise and atrial fibrillation: clinical studies and pathophysiological mechanisms.An update on hypertensive emergencies and urgencies.Coronary artery fistulas as a cause of angina: How to manage these patients?Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study.Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, EuropeaPrediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol.Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study.Midventricular dyskinesia during clozapine treatment?Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs.
P50
Q27024872-7D58EC35-00BD-4481-9F9A-37E8FC967170Q28171473-C75B862F-C5FC-4A70-9071-FA5CF51C99FDQ28218025-6B7D156B-37DC-4F78-B8F7-13BA7A1DEE13Q33163282-DC1DD18F-4C44-4FD8-9DE9-1D4D6B02CE02Q33440493-85B56201-2485-47D1-A6E7-204C3FABACF1Q33449943-E104D4E5-65E6-44F8-8863-5B9589952AEDQ33591543-850D2C5C-56AD-4D00-907D-66A0BA016D8BQ34342830-54EE1061-D0A7-4D2E-B955-3A10C334CC22Q35892692-67AA651D-617E-4E06-BF3E-D596D37FFBD9Q36853514-A9E313D7-C469-4F68-B7BB-D372658D8838Q37006863-5728DA7C-8272-4811-8596-BC3482886D88Q37046845-FC7100C1-D2CB-4B2B-BC06-A9FED1EF1341Q37130856-10E99521-022B-454B-957A-CC046D93AB28Q37320405-8FFCF318-E57B-4DFC-8BBE-EA3005B13AC4Q37387146-20FDF7D8-FC17-46E1-9899-2ABCFB193D84Q37387309-4706E9EF-7092-4779-BE90-11A87DB8E322Q37410315-B067C78E-5AE6-44FC-AB2D-5E9459A0172EQ37573908-EB76EF1F-6A19-49E3-BCE0-4F203B72EDDDQ37790731-A9ED8CEE-F6EC-4862-80F9-B1D8654B4297Q37790733-19248336-E3BA-4CCB-BF6C-BA82578F984CQ37791568-70834BFA-732D-467D-80A2-CEDA7482CA1AQ37863289-9A3D179F-4BBA-448A-BB49-38575EEE74BDQ37926954-5C95E4B3-28C4-451B-BA12-D0A98DAA775AQ38008924-010CAFE2-E745-47F8-9585-21F0604C2236Q38065851-BDDDD897-D47A-4116-97F5-1E6E8E63CFF0Q38171115-FF267993-65AE-4BB1-874B-89EF24B70DADQ38212531-2B2BEC85-73E9-48B3-8104-0ABD961B9306Q38227295-FA0983F3-AB47-4BC9-8148-07FB455284A4Q38236688-CA0A6648-3509-41C5-8609-E78A3788148AQ38282162-A9057C50-0EA7-4EE2-9CF6-14DF1242B200Q38313023-9ECD6B6E-D3C3-442D-AFF1-A09192F38270Q38484946-534ECAED-4BC3-4AD8-8F36-4799CE5BAB38Q38645328-E5E15E2B-7228-48F3-99D3-D4F8F7D833BBQ39163646-93A68E7C-79CF-4068-9AD4-E52AC5334268Q39601105-A45C7F04-A9B5-49A5-B3B7-2CE7DBCF85FFQ40126032-AC624859-3FD8-4E75-BEF6-1A7291D40DF6Q42861006-94E31FCA-0C1F-4513-B7D2-3BA1010FC5E9Q43122850-3FEA93AB-6183-4C9C-86E1-4F5334E84A49Q43261350-34DEBF32-4334-422E-9C9D-18E764906B2EQ43325780-E155596A-2E0C-4698-AC66-7C636CE20826
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Salvatore Novo
@ast
Salvatore Novo
@en
Salvatore Novo
@es
Salvatore Novo
@nl
Salvatore Novo
@sl
type
label
Salvatore Novo
@ast
Salvatore Novo
@en
Salvatore Novo
@es
Salvatore Novo
@nl
Salvatore Novo
@sl
prefLabel
Salvatore Novo
@ast
Salvatore Novo
@en
Salvatore Novo
@es
Salvatore Novo
@nl
Salvatore Novo
@sl
P106
P1153
35377068800
P21
P31
P496
0000-0002-7995-184X